Filing Flows › CV Sciences (CVSI) › Q3 2025
CV Sciences (CVSI) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
CV Sciences (CVSI) reported revenue of $3.3M for the third quarter 2025 (Q3 2025), -16% from a year earlier and -10% from the quarter before. Operating margin was -8.4%, net loss $382K (11.7% of revenue).
CV Sciences, Q3 2025: revenue $3.3M (-16% year over year), operating margin -8.4%, net loss $382K, operating cash flow −$259K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | -10% | -16% |
| Operating profit | −$275K | — | — |
| Net earnings | −$382K | — | — |
| Operating cash flow | −$259K | -190% | — |
What changed
Revenue was $3.3M in Q3 2025, down 16% year over year and down 10% from the previous quarter.
Gross margin was 48.5%, up 2.5 points from a year earlier. Operating costs exceeded revenue by $275K, an operating margin of -8.4%. Operating expenses fell 13% while revenue fell 16%. The quarter ended with a net loss of $382K, wider than the previous quarter's $261K loss.
Operating cash flow was −$259K. Non-cash charges added back $31K of depreciation and amortization and $124K of share-based compensation. Working capital and other items used $32K. Capital expenditures of $11K exceeded it, leaving free cash flow of −$270K.
Questions
What was CV Sciences' revenue in the third quarter 2025?
CV Sciences (CVSI) reported revenue of $3.3M for the third quarter 2025 (Q3 2025), -16% from a year earlier and -10% from the quarter before.
Was CV Sciences profitable in the third quarter 2025?
Operating loss was $275K (-8.4% of revenue) and net loss $382K.
Source: CV Sciences 10-Q on SEC EDGAR.